MMP2 and melanoma: When the NPs reached the melanoma, the PEG protective layer on the surface was destroyed by MMP-2 overexpressed in the melanoma and released the PD-L1 antagonist, which significantly improved the immunotherapeutic effect in combination with the inhibitor of apoptosis proteins (IAP) antagonist AZD5582 without severe toxic side effects.